Shawn Marshall Rose - 06 Jan 2026 Form 4 Insider Report for Nkarta, Inc. (NKTX)

Reporting relationship: Chief Medical Officer, Head of Research & Development
Issuer ticker: NKTX
Reported as of: 06 Jan 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 08 Jan 2026, 17:50:36 UTC
Prior SEC filing: 25 Jun 2025
Source filing: View source filing
Reporting owner signature: /s/ Bridgette Housley, as Attorney-in-Fact

Key filing fact

Shawn Marshall Rose filed Form 4 for Nkarta, Inc. (NKTX) on 08 Jan 2026.

Key facts

This page summarizes Shawn Marshall Rose's Form 4 filing for Nkarta, Inc. (NKTX).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 08 Jan 2026, 17:50.

Change

Previous filing in this sequence was filed on 25 Jun 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0002073530 Primary reporting owner

Rose Shawn Marshall

Relationship: Chief Medical Officer, Head of Research & Development
Address: C/O NKARTA, INC., 1150 VETERANS BLVD, SOUTH SAN FRANCISCO
Signature: /s/ Bridgette Housley, as Attorney-in-Fact
Signature date: 08 Jan 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

NKTX transaction

Common Stock

Award

Transaction value: $0
Shares: +70,000
Change %
Price: $0.000000
Shares after: 70,000
Date: 06 Jan 2026
Ownership: Direct
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

NKTX transaction Derivative

Stock Option (right to buy)

Award

Transaction value: $0
Shares: +139,000
Change %
Price: $0.000000
Shares after: 139,000
Date: 06 Jan 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 139,000
Exercise price: $1.93
Footnotes: F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Represents Restricted Stock Units ("RSUs") which vest in four equal annual installments beginning on January 14, 2027. Each RSU represents a contingent right to receive one share of Common Stock of the Issuer.

Footnote F2

This option is scheduled to vest and become exercisable in 48 equal monthly installments occurring on the completion of each successive month of the Reporting Person's service to the Issuer following January 14, 2026.

SEC remarks

Chief Medical Officer, Head of Research & Development